† Disclosure of Interests - Under no circumstances should any material at this site be considered as an offer to sell or a solicitation of an offer to buy an interest in any investment fund. The material on this website does not constitute, and may not be used in connection with, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not permitted by law or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer or solicitation. Access to information about any accounts is limited to investors who, among other requirements, either qualify as accredited investors within the meaning of the Securities Act of 1933, as amended, or those investors who generally are sophisticated in financial matters, such that they are capable of evaluating the merits and risks of prospective investments. Information about investing in funds affiliated with Beacon VP Capital is only available in the form of Private Placement Memoranda and other offering documents. These documents contain information to help investors evaluate a funds’ investment objectives, risks, charges and expenses, among other factors, before considering an investment. Further information about Beacon VP Capital is available in the Form ADV Part 2A & Form ADV Part 2B, filed with the SEC. Beacon VP Capital's Funds are available only to accredited investors. The content of this website and related materials are not intended to solicit investment, but rather to elicit discussion and exploration of better ways to invest. The contents of this website do not comprise an offering document. Neither historical simulations nor past return performance are necessarily indicative of future returns.

† The investment objective is to generate consistent returns that seek to outperform the S&P 500 Index. The event-driven approach to investing seeks to generate returns that are less correlated with the broader financial markets. Beacon VP Capital will seek to achieve its investment objective by investing primarily in lesser known, micro to mid-cap biotechnology and pharmaceutical companies with pharmaceutical drugs nearing or at the final stage of Food and Drug Administration (“FDA”) approval process. The Investment Manager seeks to achieve the investment objective by pursuing an investment strategy focused on scientific analysis, proprietary research and collective intelligence. The investments are expected to consist principally of a combination of securities and/or derivatives traded primarily in the United States.